NCT02486497View on ClinicalTrials.gov

Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

hENT1

hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

Sponsors
All Listed Sponsors
collaborator

IlDong Pharmaceutical Co Ltd

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02486497 - Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining | Biotech Hunter | Biotech Hunter